Biopharma successful in achieving climate-related goals, report finds
A report shows two Big Pharma companies made the top 10 in the FTSE sustainability leaderboard, yet progress against climate goals has stalled since COP26.
List view / Grid view
News
EMA’s PRAC confirms recommendation to withdraw amfepramones
The EMA’s safety board verifies that amfepramone-containing products for obesity should not be sold, due to higher-associated health risks.
EMA validates AbbVie lymphoma bispecific antibody application
AbbVie's marketing application for epcoritamab in adults with relapsed/refractory diffuse large B-cell lymphoma has been validated by the European Medicines Agency.
Outsourcing APIs put EU patients at risk
Teva warns APIs could disappear from European factories in five to 10 years if the industry does not see outsourcing essential medicine manufacture as risky.
First patient receives new engineered mRNA epigenetic
OTX-2002, a programmable epigenetic medicine is the first mRNA therapy to target MYC dysregulation and could treat hepatocellular carcinoma.
CPHI report predicts biologics outsourcing to surge in 2023
Report out ahead of CPHI Frankfurt predicts ‘biologics outsourcing to surge in 2023, as China’s innovation engine stalls.'
Astellas invests $50 million in Taysha Gene Therapies
Taysha will license AAV gene therapy candidates TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy to Astellas.
$3 trillion growth reported for biotech sector
A report reveals US job growth in the biotech industry has risen 11 percent since 2018, tipping the COVID-19 pandemic as the key driver.
NICE recommends first oral GnRH antagonist for uterine fibroids
Ryeqo, a one-per-day oral drug for adults with moderate-to-severe symptoms of uterine fibroids has been given the green light by NICE.
University of Oklahoma to open bioprocessing training facility
The centre will help prepare engineers and advance research in this emerging industry, according to Gallogly College of Engineering’s Associate Dean for Research.
ITM licenses targeted radionuclide therapy candidate
The targeted radionuclide therapy for glioblastoma is administered into a tumour cavity via a reservoir post-surgery and standard post-operative therapy.
ADC developers opt to outsource
Most developers of antibody drug conjugates choose to outsource operations to mitigate manufacturing challenges, says report.
AstraZeneca dual immunotherapy approved for US liver cancer patients
The FDA has approved Imfinzi™ combined with Imjudo for adults with unresectable liver cancer, based on a lower risk of death compared to only sorafenib.
Vaccine producers promise equal access in future pandemics
COVID-19 vaccine key players back a new proposal ensuring vaccines for future pandemics are equally distributed to all priority populations.
UK research consortium given £2 million to control monkeypox
£2 million will help fund a UK team of scientific experts to research monkeypox, uncover novel treatments and curb the spread of the virus.
